Trial Profile
A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs ABY 029 (Primary)
- Indications Soft tissue sarcoma
- Focus Diagnostic use
- 16 May 2021 Status changed from active, no longer recruiting to completed.
- 17 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 17 Dec 2020 Status changed from recruiting to active, no longer recruiting.